anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants randomized to an arm that contains the self-weighing (certain loss) component will have a balance of $3.50 at the beginning of each week of the study and each day that they do not weigh, $0.50 will be subtracted from this account. Participants will be given the IOM GWG recommendation based on their body mass index at randomization, adjusted for data collection at 36 weeks. If they achieve the goal at 36 weeks, they will receive $112 after the data collection visit. Participants will be asked to engage in 150 minutes of exercise each week based on the guideline from the ACOG. They will receive $3.50 if they meet their activity goal for the week. Otherwise, they will be notified that they would have received $3.50 had they meet their activity goal.
Guillain-Barré syndrome (GBS) is an inflammatory disease of the PNS and is the most common cause of acute flaccid paralysis, with an annual global incidence of approximately 1-2 per 100,000 person-years. Patients with GBS typically present with weakness and sensory signs in the legs that progress to the arms and cranial muscles, although the clinical presentation of the disease is heterogeneous and several distinct clinical variants exist. Diagnosis of GBS is based on the patient's history and neurological, electrophysiological, and cerebrospinal fluid (CSF) examinations. Electrophysiological studies: provide evidence of peripheral nervous system (PNS) dysfunction and can distinguish between the subtypes of GBS: acute inflammatory demyelinating polyradiculoneuropathy (AIDP), acute motor axonal neuropathy (AMAN), and acute motor-sensory axonal neuropathy (AMSAN). Disease progression can be rapid, and most patients with GBS reach their maximum disability within 2 weeks. About 20% of patients with GBS develop respiratory failure and require mechanical ventilation. Cardiac arrhythmias and blood pressure instability can occur owing to the involvement of the autonomic nervous system. Immunomodulatory therapy should be started if patients are unable to walk independently for 10 m. Evidence on treatment efficacy in patients who can still walk independently is limited, but treatment should be considered, especially if these patients display rapidly progressive weakness or other severe symptoms such as autonomic dysfunction, bulbar failure, or respiratory insufficiency. Clinical trials have demonstrated a treatment effect for intravenous immunoglobulin (IVIg) when started within 2 weeks of the onset of weakness and for plasma exchange when started within 4 weeks.
MS patients will be given approximately 15 minutes of active tDCS during MRI during the initial visit. After the first MRI visit, MS patients will receive remotely-supervised home tDCS treatment for a month to test the cumulative effects of tDCS. Participants will complete 20 x 2.0mA x 20 minute tDCS sessions paired with cognitive training over 4-week period (20 mins per day and weekend off) with electrodes placed to target the bilateral DLPFC. Around 3 months after the 20-session treatment, MS patients only will be asked to come to the clinic for neuropsychological assessments.
The invention discloses lip furuncle treating granules, relates to a method for taking a Chinese medicament orally and applying the Chinese medicament externally for treating lip furuncle and in particular relates to a method for preparing the lip furuncle treating granules and externally applied powder. The lip furuncle treating granules to be taken orally comprise the following eight main components in percentage by weight: 20% of philippine violet herb, 20% of honeysuckle flower, 10% of ginkgo seeds, 15% of platycodon root, 5% of dahurian patrinia herb, 10% of astragalus root, 5% of common anemarrhena rhizome and 15% of raw licorice root, wherein the eight Chinese medicaments are ground into ultrafine powder and prepared into the granules by adding an appropriate quantity of malt syrup. The granules are taken with warm water for three times a day after meals and 10g for each time. Usually the lip furuncle treating granules become effective after being taken for 3-5 days. If a patient feels gastrointestinal discomfort after taking the lip furuncle treating granules, the patient should stop taking the lip furuncle treating granules. The lip furuncle treating granules are not recommended for pregnant women and children. During a disease period, the patient should not eat spicy, hot or greasy food so as to prevent relapse of the lip furuncle. The externally applied powder is prepared from pear powder, indian iphigenia bulb, knoxia root, rhubarb and liquoric root which are ground into powder in a mass ratio of 5:3:3:1:1. A small amount of the externally applied powder can be applied to an infected part by using a small amount of saliva of the patient for one time every morning and evening.
This randomized controlled trial aims to assess the effects of a coach-guided ten-week videoconferencing acceptance and commitment therapy (ACT) program on mental health outcomes in depressed family caregivers of people with dementia (PwD) compared to the control group. A total of 32 family caregivers of PwD who meet the eligibility criteria will be recruited and randomized to either the intervention group or the control group. Caregivers randomly assigned to the intervention group will receive individual ACT sessions guided by a trained coach for one hour per week over 10 weeks through Zoom videoconferencing with supplemental psychoeducation materials provided. Caregivers randomly assigned to the control group will receive care as usual with psychoeducation materials provided during the study period. Outcomes regarding caregivers' mental health and ACT processes will be collected at three time points (i.e., pretest, posttest, and 3-month follow-up) and compared between groups over time. The hypotheses are that the ACT group will show improvements in depressive symptoms, other mental health outcomes, and ACT process measures at posttest and 3-month follow-up, compared to the control group.
PROBLEM TO BE SOLVED: To obtain a lipid metabolism improving and hepatic disorder suppressing agent without a fear of adverse effects by containing an extract from a plant. SOLUTION: This lipid metabolism improving and hepatic disorder suppressing agent contains an extract obtained by crushing the whole part of Phyllanthus niruri as an annual grass belonging to family Euphorgbiaceae as it is or dried, and then extracting with an organic solvent (e.g. methanol) or water, as an active ingredient. As the lipid metabolism improving agent, the extract is excellent in suppressing the elevation of triglycerides which is one of the risk factors of arteriosclerosis, and useful for the prevention and treatment of hyperlipemia, and also useful for the prevention and treatment of the lowering is hepatic functions caused by the disorder of the lipid metabolism. As the hepatic disorder suppressing agent, the extract is effective for the lowering is the hepatic functions caused by fatty liner. As a dosage, 0.1-200mg/kg per each time is administered 1-5 times a day.
BACKGROUND: Inverted papilloma (IP) is a benign tumor characterized by epithelial proliferation, which has the potential for malignant transformation. However, the mechanisms driving this transformation are poorly defined. Matrix metalloproteinase-11 (MMP-11), a regulator of the tumor microenvironment that degrades extracellular matrix, is upregulated in IP with dysplasia. Here, we aim to investigate the role of MMP-11 in IP epithelial migration and invasion.
METHODS: Human IP and contralateral normal sinus mucosa (control) samples were obtained. IP-derived epithelial cultures and normal mucosa-derived epithelial cultures were grown in air‒liquid interface, followed by immunostaining to assess MMP-11 expression in IP. Migration and invasion assays were used to evaluate the role of an anti-MMP-11 antibody on IP and control epithelial cultures.
RESULTS: IP-derived cultures demonstrated strong MMP-11 expression compared to controls. Treatment with anti-MMP-11 blocking antibody significantly reduced epithelial migration only in IP-derived cells compared to non-treated IP cells, as seen by incomplete wound closure and reduced transepithelial resistance. In addition, inhibition of MMP-11 reduced IP epithelia's ability to invade through collagen-coated transwells, suggesting that MMP-11 plays a role in invasion.
CONCLUSION: We established an in vitro model to study IP-derived epithelial cells. MMP-11 is uniquely expressed in IP epithelial cultures compared to control epithelial cultures. Inhibition of MMP-11 limits IP epithelial migration and invasion to levels similar to that of normal sinus mucosa. MMP-11 does not appear to have a functional role in normal sinus epithelium, suggesting that MMP-11 has a role in malignant transformation of IP.
Tiopronin delayed-release tablets are a reducing and cystine-binding thiol drug (CBTD) for oral use. Tiopronin is N-(2-Mercaptopropionyl) glycine and has the following structure:

Tiopronin has the empirical formula C5H9NO3S and a molecular weight of 163.20. In this drug product tiopronin exists as a dl racemic mixture.

Tiopronin is a white to off-white crystalline powder, which is freely soluble in water.

Each tiopronin delayed-release tablet contains 100 mg or 300 mg of tiopronin. The inactive ingredients in tiopronin delayed-release tablets include ammonium hydroxide, black iron oxide, colloidal silicon dioxide, hydroxypropyl cellulose, hypromellose 2910, lactose monohydrate, low-substituted hydroxypropyl cellulose, magnesium stearate, methacrylic acid ethyl acrylate copolymer, propylene glycol, shellac glaze, talc, and triethyl citrate.
Participants received Juvéderm® VOLITE, intradermal injection on a zone of 8 centimeter (cm) x 4 cm (32 cm\^2) of the volar left forearm on Day 0. The dose to be injected was decided by the investigator as per the Directions for Use. A maximum of 1 milliliter (mL) was injected on the zone treated.
Shoulder Block Suprascapular nerve block (SSNB) approach: A high-frequency linear probe was utilized across the supra-spinous fossa parallel to the spine of the scapula after skin cleaning with an antiseptic solution, if a deep block is required, a low frequency probe was required. A hyperechoic line was identified, followed by an acoustic shadow that corresponds to the floor of the supra-spinous fossa. The needle was progressed in plane from medial to lateral after local infiltration of the skin with 1% lidocaine. We directed the needle towards the lateral side of the supra-spinous fossa if the neuro-vascular bundle was not evident. After careful aspiration, 10 ml of 0.5% bupivacaine was injected under the supraspinatus muscle. Along with Axillary nerve block technique.
Methods for screening molecules or moieties for their ability to crosslink are disclosed. An aromatic carbonate, aromatic ester, or aliphatic ester group is attached to the molecule to mimic the presence of a polymer. A solution of the modified molecule is irradiated, and the first-order kinetic rate constant is measured. If the rate constant is high enough or a threshold amount of the molecule is consumed, a polymer is synthesized using the molecule/moiety as an endcap or co-monomer. The polymer is irradiated, and the increase in crosslink density and the gel formation percentage are determined. These parameters, if high enough, indicate the suitability of the molecule/moiety to act as a crosslinking agent, particularly for polycarbonates. Alternatively, the molecule/moiety may be identified as suitable solely by its first-order kinetic rate constant.
<P>PROBLEM TO BE SOLVED: To efficiently transfer only a medical image photographed with a desired region from a plurality of medical images.  <P>SOLUTION: Volume data consisting of a plurality of tomographic images (medical images) are stored in a storage unit of a data center. The region information indicating the region photographed in each tomographic image is recorded in a tag region in the tomographic image. A data server in the data center reads the volume data from the storage unit at the request for transfer transmitted from a medical facility. The data server, having read the volume data, extracts the tomographic image, in which the region indicated by the region information matches the region specified by the request for transfer, from the volume data. Then, the data server, having extracted the tomographic images, transfers the extracted tomographic image to the requesting medical facility.  <P>COPYRIGHT: (C)2008,JPO&INPIT
Sustained angiogenesis stands as a hallmark of cancer. The intricate vascular tumor microenvironment fuels cancer progression and metastasis, fosters therapy resistance, and facilitates immune evasion. Therapeutic strategies targeting tumor vasculature have emerged as transformative for cancer treatment, encompassing anti-angiogenesis, vessel normalization, and endothelial reprogramming. Growing evidence suggests the dynamic regulation of tumor angiogenesis by infiltrating myeloid cells, such as macrophages, myeloid-derived suppressor cells (MDSCs), and neutrophils. Understanding these regulatory mechanisms is pivotal in paving the way for successful vasculature-targeted cancer treatments. Therapeutic interventions aimed to disrupt myeloid cell-mediated tumor angiogenesis may reshape tumor microenvironment and overcome tumor resistance to radio/chemotherapy and immunotherapy.
White feces syndrome (WFS) is a multifactorial disease that affects global shrimp production. The diagnostic approach to identify WFS involves traditional and molecular scientific methods by examining histopathology, bioassays, PCR (polymerase chain reaction), and calorimetric estimation. The pathogenesis of WFS is closely associated with Vibrio spp., intestinal microbiota (IM) dysbiosis, and Enterocytozoon hepatopenaei (EHP). It also has caused over 10-15 % loss in the aquaculture industry and is also known to cause retardation, lethargy and slowly leading to high mortality in shrimp farms. Therefore, it is necessary to understand the molecular mechanisms processed under the association of IM dysbiosis, Vibrio spp., and EHP to analyze the impact of disease on the innate immune system of shrimp. However, only very few reviews have described the molecular pathways involved in WFS. Hence, this review aims to elucidate an in-depth analysis of molecular pathways involved in the innate immune system of shrimp and their response to pathogens. The analysis and understanding of the impact of shrimp's innate immune system on WFS would help in developing treatments to prevent the spread of disease, thereby improving the economic condition of shrimp farms worldwide.
The microcirculation hemodynamics change and inflammatory response are the two main pathophysiological mechanisms of renal ischemia-reperfusion injury (IRI) induced acute kidney injury (AKI). The treatment of microcirculation hemodynamics and inflammatory response can effectively alleviate renal injury and correct renal function. Picroside II (P II) has a wide range of pharmacological effects. Still, there are few studies on protecting IRI-AKI, and whether P II can improve renal microcirculation perfusion is still being determined. This study aims to explore the protective effect of P II on IRI-AKI and evaluate its ability to enhance renal microcirculation perfusion. In this study, a bilateral renal IRI-AKI model in mice was established, and the changes in renal microcirculation and inflammatory response were quantitatively evaluated before and after P II intervention by contrast-enhanced ultrasound (CEUS). At the same time, serum and tissue markers were measured to assess the changes in renal function. The results showed that after P II intervention, the levels of serum creatinine (Scr), blood urea nitrogen (BUN), serum cystatin C (Cys-C), kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL), tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), malondialdehyde (MDA), and superoxide dismutase (SOD), as well as the time-to-peak (TTP), peak intensity (PI) and area under the curve (AUC), and the normalized intensity difference (NID) were all alleviated. In conclusion, P II can improve renal microcirculation perfusion changes caused by IRI-AKI, reduce inflammatory reactions during AKI, and enhance renal antioxidant stress capacity. P II may be a new and promising drug for treating IRI-AKI.
The present invention discloses a human body cleaner and manufacturing method thereof. The human body cleaner comprises 1 %wt ~ 60 %wt of garlic extract, and 40 %wt ~ 99 %wt of cleaning agent. The method for manufacturing the human body cleaner comprises the following steps: preparing a plurality of garlics, adding water in a predetermined ratio to a plurality of garlics to obtain a garlic mixture, adding yeast in a predetermined ratio to the garlic mixture and leaving it to stand for a period of time for fermentation to obtain a garlic fermentation broth, performing cryogenic distillation on the garlic fermentation broth to obtain a garlic extract, and adding a cleaning agent in a predetermined ratio to the garlic extract for mixture to obtain the human body cleaner. The present invention uses the herbal human body cleaner made from garlic to clean human body and reduce symptoms of dandruff. Moreover, long-term use of the present invention will not cause either antibiotic resistance or environmental degradation. (Figure 1)
Nifedipine Extended-release Tablet is similar in appearance to a conventional tablet. It consists, however, of a semipermeable membrane surrounding an osmotically active drug core. As water from the gastrointestinal tract enters the tablet, pressure increases in the core of the tablet, releasing drug through the precision laser-drilled tablet orifice in the one side of the tablet.

Nifedipine Extended-release Tablet is designed to provide nifedipine at an approximately constant rate over 24 hours. This controlled rate of drug delivery into the gastrointestinal lumen is independent of pH or gastrointestinal motility.

Nifedipine Extended-release Tablet depends for its action on the existence of an osmotic gradient between the contents of the tablet core and fluid in the GI tract. Drug delivery is essentially constant as long as the osmotic gradient remains constant, and then gradually falls to zero. Upon swallowing, the biologically inert components of the tablet remain intact during GI transit and are eliminated in the feces as an insoluble shell.

USP Drug Release Test 5.
AIM: To compare growth in individuals with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder with population norms and to investigate the effect of gastrostomy on growth.
METHOD: The longitudinal study included 353 individuals from the International CDKL5 Disorder Database with any anthropometric measurement in baseline and/or follow-up questionnaires. The British 1990 growth reference was used to determine the age- and sex-standardized z-score. Repeated cross-sectional data were fitted using a Gaussian linear regression model with generalized estimating equations.
RESULTS: All growth parameters were below the general population norm (mean z-scores: weight -0.97, height -0.65, body mass index [BMI] -0.81, head circumference -2.12). The disparity was particularly pronounced for all anthropometric measurements after 4 years of age except for BMI. Moreover, individuals with gastrostomy placement were shown to have a larger decrease than those without.
INTERPRETATION: In addition to weight, height, and BMI, head circumference was also compromised in this disorder. Microcephaly could be considered a helpful diagnostic feature, especially in adults. Any benefit of gastrostomy on weight and BMI was mainly seen in the early years.
The present invention relates to systems and methods for real time diagnostic and data correlation utilizing a computer network. One embodiment of the present invention relates to a method for interfacing a health monitoring system with an on-line medical information site to provide real-time diagnostics and or updated research data correlation. The method includes measuring and recording at least two health related values, compiling the at least two health related values into a format consistent with an online medical information database, and transmitting the compiled versions of the at least two health related values to an online medical information database. The method may further include receiving real time diagnostics from a medical professional. The method may also include receiving updated medical research data corresponding to the transmitted values. An alternative embodiment of the present invention relates to a system for providing real time remote diagnostic and correlated research data. The system includes a medical monitoring system configured to measure at least two health related values, a remote medical database which is accessible by diagnostic medical professionals and which contains updated medical research data, and a communication link between the medical monitoring system and the remote medical database.
The invention relates to hybridoma MGD3 and the monoclonal antibody produced thereby (also called MGD3), which specifically recognises the human Dectin-1 membrane receptor. Antibody MGD3 is capable of inhibiting the binding of Dectin-1 to the natural ligand thereof, the β-glucans that are components of the fungal wall. In addition, the aforementioned antibody specifically blocks binding to  Candida albicans  and the secretion of cytokines induced thereby. The MGD3 antibody obtained enables in vitro, ex vivo and in vivo detection of the human protein Dectin-1. Similarly, said antibody can be used to detect the level of expression of the receptor in human leukocytes, to define the role of this receptor in the pathogenesis of autoimmune illnesses and of conditions characterised by chronic inflammation and to ascertain the therapeutic effect of different anti-inflammatory and immunosuppressor agents. In addition, the MGD3 antibody may have therapeutic potential in chronic inflammatory illnesses.
Safety and effectiveness of BRIVIACT have been established in pediatric patients 1 month to less than 16 years of age. Use of BRIVIACT in these age groups is supported by evidence from adequate and well-controlled studies of BRIVIACT in adults with partial-onset seizures, pharmacokinetic data from adult and pediatric patients, and safety data in pediatric patients 2 months to less than 16 years of age [see Dosage and Administration (2.1), Warnings and Precautions (5.3), Adverse Reactions (6.1), Clinical Pharmacology (12.3), and Clinical Studies (14)].

Safety and effectiveness in pediatric patients below the age of 1 month have not been established.

Juvenile Animal Toxicity Data

The potential adverse effects of brivaracetam on postnatal growth and development were investigated in juvenile rats and dogs. Oral administration (0, 150, 300, or 600 mg/kg/day) to rats during the neonatal and juvenile periods of development (approximately equivalent to neonatal through adolescent development in humans) resulted in increased mortality, decreased body weight gain, delayed male sexual maturation, and adverse neurobehavioral effects at the highest dose tested and decreased brain size and weight at all doses. Therefore, a no-effect dose was not established; the lowest dose tested in juvenile rats was associated with plasma exposures (AUC) approximately 2 times those in children and adolescents at the recommended maintenance dose. In dogs, oral administration (0, 15, 30, or 100 mg/kg/day) throughout the neonatal and juvenile periods of development induced liver changes similar to those observed in adult animals at the highest dose but produced no adverse effects on growth, bone density or strength, neurological testing, or neuropathology evaluation. The overall no-effect dose (30 mg/kg/day) and the no-effect dose for adverse effects on developmental parameters (100 mg/kg/day) were associated with plasma exposures approximately equal to and 4 times, respectively, those in children and adolescents at the recommended maintenance dose.